Literature DB >> 18181740

Clinical findings, therapeutic approach, and outcome of brucellar vertebral osteomyelitis.

Juan D Colmenero1, Juan D Ruiz-Mesa, Antonio Plata, Pilar Bermúdez, Patricia Martín-Rico, María I Queipo-Ortuño, José M Reguera.   

Abstract

BACKGROUND: Osteoarticular complications are the most common focal complications of brucellosis. Although vertebral osteomyelitis is the most frequent location in adults >30 years of age, little information is available about this serious complication of brucellosis, and great confusion surrounds its prognosis and the most appropriate treatment.
METHODS: We undertook a descriptive, retrospective, observational study of 96 patients who received a diagnosis of brucella vertebral osteomyelitis from September 1982 through December 2005 at a tertiary care hospital. All of the patients were treated for 3 months, after which they were followed up monthly for the first 3 months and then at 2-month intervals for the subsequent 6 months.
RESULTS: The incidence of vertebral osteomyelitis was 10.4%. The mean diagnostic delay was 12.7 weeks. Inflammatory spinal pain (occurring in 94.8% of patients) and fever (91.7%) were the most relevant clinical characteristics. Eight patients (8.3%) had motor weakness or paralysis. Paravertebral masses, epidural masses, and psoas abscesses were detected in 45.8%, 27.1%, and 10.4% of patients, respectively. Sixty-three patients (65.6%) received medication only, and 33 (34.4%) required surgical therapy in addition to medication. Twenty percent of patients experienced therapeutic failure. Attributable mortality was 2.1%, and severe functional sequelae were apparent in 6.2% of the patients. No significant differences were seen between patients who were treated with doxycycline-streptomycin and those treated with doxycycline-rifampicin.
CONCLUSIONS: Vertebral osteomyelitis is a serious complication of brucellosis. It generates a high rate of therapeutic failure and functional sequelae. In the absence of more-powerful controlled studies, the duration of treatment of brucellar vertebral osteomyelitis should be 3 months.

Entities:  

Mesh:

Year:  2008        PMID: 18181740     DOI: 10.1086/525266

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  29 in total

1.  Serum annexin A2 levels in acute brucellosis and brucellar spondylodiscitis.

Authors:  N Aktug Demir; S Kolgelier; S Sumer; A C Inkaya; S Ozcimen; L S Demir; O Ural; A Arpaci
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-23       Impact factor: 3.267

2.  Chronic, progressive back pain, fever and a noticeable paravertebral mass.

Authors:  Homarh Villaverde; Eduardo Gotuzzo; Carlos Seas
Journal:  Am J Trop Med Hyg       Date:  2011-03       Impact factor: 2.345

3.  Negative serology: could exclude the diagnosis of brucellosis?

Authors:  Aygul Dogan Çelik; Zerrin Yulugkural; Cumhur Kilincer; Mustafa Kemal Hamamcioglu; Figen Kuloglu; Filiz Akata
Journal:  Rheumatol Int       Date:  2010-04-09       Impact factor: 2.631

4.  Spinal epidural abscess in brucellosis.

Authors:  Ahmet Boyaci; Nurefsan Boyaci; Ahmet Tutoglu; Dilek Sen Dokumaci
Journal:  BMJ Case Rep       Date:  2013-09-26

5.  Joint EANM/ESNR and ESCMID-endorsed consensus document for the diagnosis of spine infection (spondylodiscitis) in adults.

Authors:  Elena Lazzeri; Alessandro Bozzao; Maria Adriana Cataldo; Nicola Petrosillo; Luigi Manfrè; Andrej Trampuz; Alberto Signore; Mario Muto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-09       Impact factor: 9.236

6.  IFN-γ-deficient mice develop IL-1-dependent cutaneous and musculoskeletal inflammation during experimental brucellosis.

Authors:  Jerod A Skyberg; Theresa Thornburg; Irina Kochetkova; William Layton; Gayle Callis; MaryClare F Rollins; Carol Riccardi; Todd Becker; Sarah Golden; David W Pascual
Journal:  J Leukoc Biol       Date:  2012-05-25       Impact factor: 4.962

7.  Brucellar spondylodiscitis: comparison of patients with and without abscesses.

Authors:  Figen Kaptan; Hakki Mustafa Gulduren; Aysegul Sarsilmaz; Hasan Kamil Sucu; Serap Ural; Ilknur Vardar; Nejat Ali Coskun
Journal:  Rheumatol Int       Date:  2012-07-29       Impact factor: 2.631

8.  Proinflammatory response of human osteoblastic cell lines and osteoblast-monocyte interaction upon infection with Brucella spp.

Authors:  M Victoria Delpino; Carlos A Fossati; Pablo C Baldi
Journal:  Infect Immun       Date:  2008-12-22       Impact factor: 3.441

9.  Complicated brucellar spondylodiscitis: experience from an endemic area.

Authors:  Aysegul Ulu-Kilic; Merve Sefa Sayar; Ediz Tütüncü; Figen Sezen; Irfan Sencan
Journal:  Rheumatol Int       Date:  2012-11-04       Impact factor: 2.631

10.  Brucella abortus invasion of synoviocytes inhibits apoptosis and induces bone resorption through RANKL expression.

Authors:  Romina Scian; Paula Barrionuevo; Ana María Rodriguez; Paula Constanza Arriola Benitez; Clara García Samartino; Carlos Alberto Fossati; Guillermo Hernán Giambartolomei; María Victoria Delpino
Journal:  Infect Immun       Date:  2013-03-18       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.